Patent Filed For Banking Of Autologous Neurogenic Cells In Professional Athletes At Risk Of CTE

Creative Commons License Source:  Keith Johnston , no changes made.
Advertisement img

Therapeutics Solutions International, Inc., has announced the addition and expansion to their chronic traumatic encephalopathy (CTE) portfolio of intellectual property with the filing of a new patent application. The invention is in the field of cellular therapies, more particularly, the invention pertains to the use of autologous cell banking, and the manipulation of autologous cells for treatment of CTE.

Therapeutic Solutions International, founded in 2011, headquartered in Oceanside, California, USA, is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.

CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

Featured Partners

“This new means of obtaining autologous cells and banking them for use in the treatment and prevention of CTE is a new and novel approach. The autologous regenerative cells are banked for future administration in the same patient when the patient begins to develop signs of CTE or possesses an upregulation of markers associated with the probability of CTE onset,” – Tim G. Dixon, CEO & President of Therapeutic Solutions International, Inc.

“Banking of autologous cells is a well-known procedure which has generated considerable revenue despite little practical value. For example, the only FDA approved means of utilizing cord blood cells is for treatment of pediatric leukemias, however, in these situations, allogeneic cells are required due to the possibility of autologous cells possessing proclivity towards leukemic transformation. The current patent provides tissue banking means for athletes at risk of CTE and means of utilizing the autologous cells,” … “The possibility of using regenerative cells such as stem cells is limited by a lack of autologous cell sources. Our invention provides means of banking and utilizing autologous cells for use in patients with CTE.” – Dr. Thomas Ichim, Board Member of Therapeutic Solutions International.